Skip to main content
OpenTrials
Completed

NCT Number: NCT05541081

Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe

A prospective interventional study to evaluate a strategy of point-of-care testing for sexually transmitted infections including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Sexually transmitted infections (STIs) can cause serious morbidity including pelvic inflammatory disease, infertility, poor mental health, adverse pregnancy outcomes and an increased risk of HIV transmission. In low and middle-income countries (LMICs), STIs are treated using syndromic management, which has poor sensitivity and specificity, leading to considerable levels of both underdiagnosis and overtreatment. In recent years, simpler diagnostic platforms for STIs have been developed. Development and evaluation of strategies for provision of diagnostic testing in LMICs are needed and the World Health Organization (WHO) has called for evidence to inform replacement of syndromic management by diagnostic testing.

The aim of this project is to evaluate a strategy of point-of-care (POC) testing for STIs including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe.

The objectives are to:

  • Determine the uptake, prevalence and yield of chlamydia, gonorrhoea, trichomoniasis, syphilis and hepatitis B testing, and risk factors for infection among women attending for antenatal care
  • Assess the acceptability and feasibility of this intervention
  • Estimate the cost and cost-effectiveness of POC STI testing
  • Investigate the prevalence of antimicrobial resistance for Neisseria gonorrhoeae to inform the development of a gonococcal antimicrobial resistance surveillance programme
  • Assess an incentives-based approach to optimize uptake of client-referral partner notification.

A prospective interventional study will be conducted in three primary healthcare clinics (PHCs) in Harare province, Zimbabwe. 1000 pregnant women will be recruited over a nine month period when registering for routine antenatal care. Testing will be staggered across sites so that testing will be available at each site for three months within the nine-month study period. All Identified STIs will be managed comprehensively including treatment and/or referral if required according to national guidelines, and partner notification and risk reduction counselling.

Given the relatively low number of gonococcal isolates likely to be obtained from pregnant women alone, men attending the PHCs with urethral discharge will be recruited to gain sufficient numbers to establish a surveillance programme. Urethral samples will be collected from 140 men with urethral discharge, to support the assessment of antimicrobial resistance amongst patients with gonorrhoea.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant woman
  • Attending a study site for antenatal care

Exclusion criteria

  • Enrolment in this study on a previous antenatal visit
  • Unable to provide consent in English or Shona

Treatment and study plan

Point-of-care STI testing

Diagnostic Test

Testing for:

  • Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)
  • Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)
  • HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)
  • Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)

Primary outcomes

  1. Composite STI prevalence

    Time frame: Through study completion, up to 1 year

    Composite % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and/or hepatitis B

  2. Individual STI prevalences

    Time frame: Through study completion, up to 1 year

    Individual % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and hepatitis B

Secondary outcomes

  1. Uptake of STI testing

    Time frame: Through study completion, up to 1 year

    % of individuals approached who accept and undergo testing

  2. Yield of STI testing

    Time frame: Through study completion, up to 1 year

    % of individuals approached who test positive for an STI

  3. Uptake of treatment

    Time frame: Through study completion, up to 1 year

    % of participants with a curable STI who accept treatment

  4. Uptake of partner notification

    Time frame: Through study completion, up to 1 year

    % of participants with a curable STI who undertake partner notification

  5. Prevalence of antimicrobial resistance in gonococcal isolates

    Time frame: Through study completion, up to 1 year

    % of gonococcal isolates with resistance to ceftriaxone, cefixime, azithromycin, and ciprofloxacin

  6. Prevalence of adverse birth outcomes

    Time frame: Through study completion, up to 2 years

    % of pregnancies with premature birth, miscarriage, or low birth weight

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Collaborators

  • Biomedical Research and Training Institute

Registry information

Acronym: IPSAZ

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Sep 15, 2022
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.